Newron Pharmaceuticals SpA (SWX: NWRN) has agreed to acquired Hunter-Fleming Ltd., a UK-based developer of drugs to treat neurodegenerative and inflammatory disorders. The deal includes an upfront payment of EUR 8 million, plus up to EUR 17 million in earnouts (payable in Newron shares). Hunter-Fleming has raised over $20 million in VC funding from firms like Advent International, Equity Ventures Ltd., Yorkshire Fund Managers, MTI Partners and Bridgepoint Capital.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.